Treatment of Latent TB Infection (LTBI)

Slides:



Advertisements
Similar presentations
Contact Evaluation Your name Institution/organization Meeting Date International Standards 18, 19.
Advertisements

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Your name Institution/organization Meeting Date. Introduction.
TB/HIV Research Priorities: TB Preventive Therapy.
TB Disease and Latent TB Infection
Targeted Tuberculosis (TB) Testing and Treatment of Latent TB Infection December 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Tuberculosis in Children: Prevention Module 10C - March 2010.
Continuity Clinic Tuberculosis. Continuity Clinic Objectives Know current epidemiologic trends in TB Know indications for testing for TB exposure and.
Tuberculosis Control What’s New. TB Regional Nurse Update Teri Lee Dyke, RN, BSN, CIC Julie McCallum, RN, MPH Regional TB Nurse Consultants.
Wyoming Department of Health Communicable Diseases
7. Anti-TB regimen in special situations of liver disease, renal impairment, and pregnancy.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Jean-Pierre Zellweger Swiss Lung Association Berne, Switzerland
Tuberculosis (TB) PHCL 442 Lab Discussion Jamilah Al-Saidan, M.Sc.
Tuberculosis Presented by Vivian Pham and Vivian Nguyen.
Unit 5: IPT Isoniazid TB Preventive Therapy
Diagnosing and Treating Latent TB Infection (LTBI)
The danger Numero Uno. That’s how it reaches you Unprotected sexual intercourse Intravenous drug abuse and shared needles From a HIV positive mother to.
Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.
TUBERCULOSIS Chokechai Rongkavilit Pediatric Infectious Diseases.
Pulmonary TB. BY PROF. AZZA EL- MEDANY Department of Pharmacology.
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
TB (Infection) or not TB? Who should we screen and treat? Primary Care Conference August 31, 2005 K. Mae Hla, M.D., M.H.S.
بسم الله الرحمن الرحيم. A 25 year old Saudi male applied to work as paramedic. He has no symptoms or history of contact with sick patients. His physical.
1 Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection, 2005 Applying CDC/ATS Guidelines in Your Clinical Practice Division of Tuberculosis.
Core Curriculum Contents Introduction Transmission and Pathogenesis Epidemiology of TB in the U.S. Testing for TB Disease and Infection Diagnosis of TB.
Core Curriculum Contents Introduction Transmission and Pathogenesis Epidemiology of TB in the U.S. Testing for TB Disease and Infection Diagnosis of TB.
Chemotherapy of Tuberculosis By Prof. Azza El-Medany.
Mantoux tuberculin skin test
Tuberculosis Dr Hafsa Raheel, MBBS, MCPS, FCPS Department of Family and Community Medicine KSU.
SPECIAL CONSIDERATIONS August
Pulmonary TB. BY PROF.  AZZA ELMedany OBJECTIVES  At the end of lecture, the students should:  Discuss the etiology of tuberculosis  Discuss the.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Core Curriculum Contents Introduction Transmission and Pathogenesis Epidemiology of TB in the U.S. Testing for TB Disease and Infection Diagnosis of TB.
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
TB Disease and Infection
Tuberculosis (TB) PHCL 442 Lab Discussion 4 Raniah Al-Jaizani M.Sc.
Management of the Newborn When Maternal TB Suspected
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
Fundamentals of Tuberculosis (TB)
[More] Respiratory Disorders
Applying CDC/ATS Guidelines in Your Clinical Practice
Infant born with mother Tuberculosis
Treatment of TB Disease
Treatment algorithm for tuberculosis
Copyright © 2006 American Medical Association. All rights reserved.
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
This is an archived document.
Figure 1. Paradigm for evaluation of those with latent tuberculosis infection (LTBI) based on risk of infection, risk of progression to tuberculosis, and.
Treatment algorithm for tuberculosis
This is an archived document.
Tuberculosis (TB) Fundamentals for School Nurses
بسم الله الرحمن الرحيم.
Marie Turner, M.D. Jo-Ann Keegan, R.N., M.S.N.
WHO Consolidated guidelines for TB preventive treatment:
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
Tb: Screening & Diagnosis (1)
Anthony D Harries Ministry of Health, Malawi
Anti Tuberculosis Norah A A AL KHATHLAN MD 4/18/2019 Failure or MDR_TB.
Latent TB Infection (LTBI)
5th edition NTP MANUAL OF PROCEDURES Case Finding
Presentation transcript:

Treatment of Latent TB Infection (LTBI) This is an archived document. Treatment of Latent TB Infection (LTBI)

Candidates for Treatment of LTBI Positive skin test result $5 mm HIV-positive persons Recent contacts of a TB case Persons with fibrotic changes on chest radiograph consistent with old TB Patients with organ transplants and other immunosuppressed patients

Candidates for Treatment of LTBI (cont.) Positive skin test result $10 mm Recent arrivals from high-prevalence countries Injection drug users Residents and employees of high-risk congregate settings Mycobacteriology laboratory personnel Persons with clinical conditions that make them high-risk Children < 4 years of age, or children and adolescents exposed to adults in high-risk categories

Candidates for Treatment of LTBI (cont.) Positive skin test result $15 mm Persons with no known risk factors for TB may be considered Targeted skin testing programs should only be conducted among high-risk groups

Treatment of LTBI with Isoniazid (INH) 9-month regimen considered optimal Children should receive 9 months of therapy Can be given twice-weekly if directly observed

Treatment of LTBI with a Rifamycin and Pyrazinamide (PZA) HIV-Positive Persons A rifamycin and PZA daily for 2 months May be given twice weekly Administration of rifampin (RIF) contraindicated with some protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) HIV-Negative Persons Clinical trials have not been conducted Daily RIF and PZA for 2 months

Contacts of Multidrug-Resistant TB Contacts of INH-Resistant TB Treatment with a rifamycin and PZA If unable to tolerate PZA, 4-month regimen of daily RIF HIV-positive persons: 2 month regimen with a rifamycin and PZA Contacts of Multidrug-Resistant TB Use 2 drugs to which the infecting organism has demonstrated susceptibility Treat for 6 months or observe without treatment (HIV-negative) Treat HIV-positive persons for 12 months Follow for 2 years regardless of treatment

Pregnancy and Breast-feeding Fibrotic Lesions Acceptable regimens include 9 months of INH 2 months RIF plus PZA 4 months of RIF (with or without INH) Pregnancy and Breast-feeding INH daily or twice weekly Pyridoxine supplementation Breast-feeding not contraindicated

Monitoring Patients Before treatment for LTBI is started, clinicians should Rule out possibility of TB disease Determine history of treatment for LTBI or disease Determine contraindications to treatment Obtain information about current and previous drug therapy Recommend HIV testing if risk factors are present

Monitoring Patients (cont.) Establish rapport with patient and emphasize Benefits of treatment Importance of adherence to treatment regimen Possible adverse side effects of regimen Establishment of optimal follow-up plan

Monitoring Patients (cont.) Baseline laboratory testing Not routinely indicated Baseline hepatic measurements for Patients whose initial evaluation suggests a liver disorder Patients with HIV infection Pregnant women and those in immediate postpartum period Patients with history of chronic liver disorder

Monitoring Patients (cont.) At least monthly, evaluate for Adherence to prescribed regimen Signs and symptoms of active TB disease Signs and symptoms of hepatitis (if receiving isoniazid alone, and at 2, 4, and 8 weeks if receiving RIF and PZA)